Antoni Ribas
#74,887
Most Influential Person Now
Spanish-American physician‐scientist
Antoni Ribas 's AcademicInfluence.com Rankings
Antoni Ribas philosophy Degrees
Philosophy
#2641
World Rank
#4449
Historical Rank
Logic
#687
World Rank
#1195
Historical Rank
Antoni Ribas biology Degrees
Biology
#3074
World Rank
#4757
Historical Rank
Immunology
#122
World Rank
#129
Historical Rank
Download Badge
Philosophy Biology
Antoni Ribas 's Degrees
- Doctorate Medicine University of Barcelona
- PhD Immunology University of Barcelona
Why Is Antoni Ribas Influential?
(Suggest an Edit or Addition)According to Wikipedia, Antoni Ribas is a Spanish-American physician–scientist. He is a Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California, Los Angeles and Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center. Ribas served as president of the American Association for Cancer Research in 2021–2022.
Antoni Ribas 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
- PD-1 blockade induces responses by inhibiting adaptive immune resistance (2014) (4971)
- Pembrolizumab versus Ipilimumab in Advanced Melanoma. (2015) (4517)
- Inhibition of mutated, activated BRAF in metastatic melanoma. (2010) (3502)
- Cancer immunotherapy using checkpoint blockade (2018) (3364)
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. (2013) (3189)
- Genetic basis for clinical response to CTLA-4 blockade in melanoma. (2014) (3103)
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy (2017) (2836)
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles (2010) (2274)
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. (2016) (2127)
- Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) (2115)
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation (2010) (2097)
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (2012) (2035)
- Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. (2014) (1716)
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (2010) (1645)
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial (2014) (1524)
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion (2012) (1516)
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (2015) (1348)
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (2016) (1323)
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) (2011) (1296)
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy (2018) (1272)
- IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade (2017) (1232)
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors (2012) (1093)
- Classifying Cancers Based on T-cell Infiltration and PD-L1. (2015) (1070)
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2017) (980)
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression (2017) (944)
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017) (883)
- Targeted agents and immunotherapies: optimizing outcomes in melanoma (2017) (867)
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. (2017) (858)
- Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (2014) (835)
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. (2016) (831)
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (2017) (778)
- Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. (2016) (712)
- Combination cancer immunotherapies tailored to the tumour microenvironment (2016) (696)
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
- Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. (2013) (681)
- Hepatotoxicity with combination of vemurafenib and ipilimumab. (2013) (668)
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab (2016) (618)
- Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance (2012) (614)
- RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. (2012) (610)
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. (2019) (606)
- Tumor immunotherapy directed at PD-1. (2012) (590)
- Tumour-intrinsic resistance to immune checkpoint blockade (2019) (588)
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. (2016) (572)
- IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade (2017) (570)
- Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. (2005) (565)
- PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. (2011) (519)
- The “cancer immunogram” (2016) (504)
- Reprogramming human T cell function and specificity with non-viral genome targeting (2017) (503)
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance (2015) (482)
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma (2014) (475)
- Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. (2018) (470)
- Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. (2016) (468)
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma (2015) (462)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack. (2015) (437)
- Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. (2013) (432)
- A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells (2011) (389)
- Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. (2013) (381)
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. (2018) (377)
- Single-cell analysis tools for drug discovery and development (2015) (352)
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. (2013) (346)
- Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients (2014) (342)
- HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression (2009) (328)
- Multiple early factors anticipate post-acute COVID-19 sequelae (2022) (313)
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. (2017) (310)
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019) (307)
- Genetic Mechanisms of Immune Evasion in Colorectal Cancer. (2018) (305)
- Current developments in cancer vaccines and cellular immunotherapy. (2003) (300)
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (2014) (300)
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? (2015) (297)
- Phase I/II trial of tremelimumab in patients with metastatic melanoma. (2009) (294)
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma (2014) (293)
- PD-1 Blockade Expands Intratumoral Memory T Cells (2016) (288)
- Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA (2014) (283)
- Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. (2015) (275)
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. (2016) (270)
- Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. (2003) (267)
- sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (251)
- LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) (251)
- Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. (2014) (247)
- Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. (2014) (244)
- BRAF targeted therapy changes the treatment paradigm in melanoma (2011) (241)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 (2010) (234)
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade (2018) (234)
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. (2017) (233)
- Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. (2014) (231)
- Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. (2016) (231)
- Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers (2018) (231)
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers (2015) (230)
- Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. (2014) (229)
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
- An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. (2016) (229)
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (2019) (228)
- What does PD-L1 positive or negative mean? (2016) (228)
- Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma (1997) (221)
- Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy (2016) (218)
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma (2019) (216)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (216)
- Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. (2011) (215)
- High response rate to PD-1 blockade in desmoplastic melanomas (2017) (210)
- BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. (2012) (209)
- Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. (2014) (207)
- Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. (2015) (206)
- The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma (2016) (204)
- Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (204)
- Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes (2018) (199)
- IFN-g – related mRNA profile predicts clinical response to PD-1 blockade (2019) (198)
- BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. (2012) (197)
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations (2018) (196)
- Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065)) (2017) (196)
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (2018) (195)
- Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. (1997) (194)
- Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction (2020) (194)
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway (2011) (193)
- Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. (2013) (191)
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. (2017) (190)
- A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides (2006) (184)
- MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells (2015) (184)
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. (2015) (183)
- Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma (2014) (183)
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. (2018) (182)
- SnapShot: Immune Checkpoint Inhibitors. (2017) (175)
- Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma (2008) (174)
- Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion (2012) (172)
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2018) (171)
- Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. (1999) (170)
- Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (2017) (169)
- T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. (2003) (166)
- Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance (2017) (164)
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms (2012) (164)
- Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. (2012) (164)
- Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. (1998) (164)
- Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
- Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death (2012) (161)
- Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. (2015) (159)
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. (2019) (157)
- A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. (2014) (157)
- CTLA4 blockade increases Th17 cells in patients with metastatic melanoma (2009) (155)
- Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. (2020) (154)
- A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. (2011) (153)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. (2007) (150)
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
- BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (2011) (142)
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
- Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer (2010) (141)
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations (2010) (140)
- Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. (2009) (139)
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans (2011) (139)
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. (2016) (139)
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. (2013) (138)
- A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. (2006) (133)
- α-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma (1999) (133)
- Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. (2017) (131)
- Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. (2005) (127)
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade (2009) (123)
- Clinical development of the anti-CTLA-4 antibody tremelimumab. (2010) (122)
- T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human α Fetoprotein1 (2001) (120)
- Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. (2013) (119)
- Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma (2008) (119)
- Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy (2004) (118)
- Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
- Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. (2017) (118)
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. (2020) (115)
- Ionizing Radiation Affects Human MART-1 Melanoma Antigen Processing and Presentation by Dendritic Cells1 (2004) (114)
- A phase 2 clinical trial of nab‐paclitaxel in previously treated and chemotherapy‐naive patients with metastatic melanoma (2009) (113)
- Determinant spreading and tumor responses after peptide-based cancer immunotherapy. (2003) (112)
- Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. (2016) (112)
- MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. (2017) (111)
- Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. (2018) (110)
- Targeted Therapies to Improve Tumor Immunotherapy (2008) (109)
- p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. (1999) (106)
- Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (2016) (104)
- Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells (2011) (103)
- Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (103)
- alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. (2001) (103)
- Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells (2016) (102)
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? (2009) (99)
- T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy (2008) (99)
- Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. (2012) (98)
- Targeting oncogenic drivers and the immune system in melanoma. (2013) (97)
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (97)
- Releasing the Brakes on Cancer Immunotherapy. (2015) (92)
- Evaluation of pre-analytical factors affecting plasma DNA analysis (2017) (90)
- A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (90)
- Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab (2010) (90)
- Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. (2018) (89)
- T cell antigen discovery via trogocytosis (2019) (89)
- Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL (2018) (88)
- Cancer immunotherapy using gene-modified dendritic cells. (2002) (87)
- Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. (2015) (87)
- In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. (1997) (86)
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade (2014) (86)
- 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. (2018) (86)
- Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative (2014) (86)
- Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. (2009) (84)
- Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study (2020) (83)
- Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. (1999) (83)
- Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations (2011) (83)
- Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006 (2018) (81)
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (81)
- T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. (2001) (81)
- Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma (2015) (81)
- T cell antigen discovery via Signaling and Antigen presenting Bifunctional Receptors (2019) (81)
- Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes (2014) (81)
- Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma (2014) (80)
- New Challenges in Endpoints for Drug Development in Advanced Melanoma (2011) (80)
- The state of melanoma: challenges and opportunities (2016) (79)
- Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma (2008) (79)
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma (2020) (78)
- Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study (2017) (78)
- Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (2018) (77)
- Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 (2015) (76)
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma (2014) (75)
- Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. (2000) (75)
- Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. (2014) (74)
- Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application (2011) (73)
- PAK4 inhibition improves PD-1 blockade immunotherapy (2019) (72)
- Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. (2015) (72)
- Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines (2012) (72)
- Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512 (2012) (71)
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. (2016) (70)
- Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses (2010) (70)
- Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial (2011) (70)
- Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 (2015) (70)
- DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134. (2021) (69)
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. (2020) (69)
- Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. (2015) (68)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1 (2006) (67)
- Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. (2013) (67)
- Genetically modified dendritic cells for cancer immunotherapy. (2005) (66)
- Human Dendritic Cell Maturation by Adenovirus Transduction Enhances Tumor Antigen-Specific T-Cell Responses (2004) (66)
- Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. (2015) (66)
- Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. (2016) (65)
- NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain1 (2006) (65)
- The new era of adjuvant therapies for melanoma (2018) (64)
- Precise T cell recognition programs designed by transcriptionally linking multiple receptors (2020) (64)
- Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer (2007) (64)
- Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials (2018) (60)
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i (2020) (59)
- Combining cancer immunotherapy and targeted therapy. (2013) (59)
- Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain (2008) (59)
- Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma (2020) (57)
- Assessing oncologic benefit in clinical trials of immunotherapy agents. (2010) (57)
- Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. (2015) (57)
- Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood (2019) (57)
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial (2020) (57)
- Overcoming genetically-based resistance mechanisms to PD-1 blockade. (2019) (56)
- Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. (2017) (56)
- Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. (2000) (56)
- New drug targets in metastatic melanoma (2014) (55)
- Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line (2020) (55)
- JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma (2016) (54)
- MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. (2010) (54)
- Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. (1996) (53)
- Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin‐based chemotherapy (1992) (52)
- A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab (2018) (52)
- Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. (2021) (52)
- Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma (2018) (52)
- Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist (2020) (51)
- CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. (2001) (51)
- Immunomodulation by imiquimod in patients with high-risk primary melanoma (2011) (51)
- Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles. (2020) (51)
- Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial (2020) (50)
- Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). (2008) (50)
- Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition (2015) (50)
- Anti-CTLA4 Antibody Clinical Trials in Melanoma. (2007) (50)
- Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma (2016) (50)
- Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. (2016) (49)
- Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? (2016) (49)
- Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development (2014) (49)
- Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. (2016) (49)
- CD4+CD25− T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model1 (2008) (47)
- Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells (2020) (47)
- T-cell immunotherapy: looking forward. (2014) (47)
- Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). (2011) (47)
- Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma (2015) (47)
- A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" (2008) (46)
- Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology (2009) (46)
- Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules (2018) (46)
- Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer (2019) (46)
- Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. (2019) (45)
- KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. (2018) (45)
- Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. (2013) (44)
- A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States (2014) (44)
- Gauging the Long-Term Benefits of Ipilimumab in Melanoma. (2015) (44)
- Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen (2008) (44)
- IFNg is Critical for CAR T Cell Mediated Myeloid Activation and Induction of Endogenous Immunity. (2021) (44)
- Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma (2009) (44)
- Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells (1999) (44)
- Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors (2016) (44)
- Anti-PD-1 therapy in melanoma. (2015) (44)
- Update on immunotherapy for melanoma. (2006) (44)
- Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (44)
- Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays (2006) (43)
- Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. (2018) (43)
- Targeted Therapy for Melanoma. (2016) (43)
- Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. (2000) (43)
- ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways (2017) (42)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
- Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (42)
- Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027)) (2018) (42)
- Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome (2014) (41)
- Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response (2019) (41)
- The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics (2014) (41)
- Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study (2018) (40)
- New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone (2017) (40)
- Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. (2010) (40)
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma (2022) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. (2019) (39)
- Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts). (2011) (39)
- mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
- Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma (2007) (39)
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion (2012) (38)
- Disparities in Cancer Prevention in the COVID-19 Era (2020) (38)
- siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. (2011) (38)
- Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma (2020) (38)
- 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study (2021) (38)
- Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. (2021) (38)
- PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2020) (37)
- Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors (2015) (37)
- COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors (2014) (37)
- Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. (2000) (37)
- PET Imaging of Cancer Immunotherapy (2008) (36)
- 1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma (2017) (36)
- Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway (2011) (36)
- Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. (2007) (36)
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. (2020) (35)
- Feasibility Trial of Methotrexate–Paclitaxel as a Second Line Therapy in Advanced Urothelial Cancer (2002) (35)
- Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma (2021) (35)
- Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors (2010) (35)
- P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma (2015) (35)
- 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. (2018) (35)
- Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma (2020) (34)
- Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma (2010) (34)
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (2019) (34)
- MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor (2017) (34)
- Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations (2013) (34)
- Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells (2005) (34)
- Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition (2019) (33)
- Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). (2014) (33)
- Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386) (2018) (33)
- Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance (2019) (33)
- A β-Camera Integrated with a Microfluidic Chip for Radioassays Based on Real-Time Imaging of Glycolysis in Small Cell Populations (2011) (33)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
- Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. (2015) (32)
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. (2019) (32)
- 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) (2021) (32)
- Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study (2017) (32)
- Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma (2005) (32)
- Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma (2015) (32)
- Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma (2019) (31)
- Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. (2013) (31)
- Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib (2017) (31)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
- Dendritic Cell–Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma: Efficacy, Safety, and Activity of Ad-GM·CAIX in Immunocompetent Mouse Models (2013) (30)
- 6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 (2009) (30)
- LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES (2014) (30)
- Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). (2015) (29)
- Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. (1996) (29)
- High frequency of brain metastases after adjuvant therapy for high‐risk melanoma (2017) (28)
- Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells1 (2004) (28)
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. (2018) (27)
- Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma. (2012) (27)
- Genetic immunotherapy for cancer. (2000) (27)
- Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma (2010) (27)
- HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. (2014) (27)
- Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma (2016) (27)
- A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) (2015) (27)
- Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. (2015) (26)
- Non-viral precision T cell receptor replacement for personalized cell therapy (2022) (26)
- coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2015) (26)
- Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity. (2020) (25)
- Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial. (2010) (25)
- CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893 (2010) (25)
- RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. (2021) (25)
- Cardiotoxicities of novel cancer immunotherapies (2021) (24)
- Accelerated wound healing by injectable star poly(ethylene glycol)‐b‐poly(propylene sulfide) scaffolds loaded with poorly water‐soluble drugs (2018) (24)
- PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. (2009) (24)
- Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy (2021) (24)
- Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma (2019) (24)
- A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors (2016) (23)
- The Impact of Ex Vivo Clinical Grade Activation Protocols on Human T-cell Phenotype and Function for the Generation of Genetically Modified Cells for Adoptive Cell Transfer Therapy (2010) (23)
- Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (2011) (23)
- Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 (2022) (23)
- Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. (1999) (23)
- Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. (2012) (22)
- Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study. (2018) (22)
- [The ISCA (Systematic Interview of Alcohol Consumption), a new instrument to detect risky drinking]. (2001) (22)
- Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach (2020) (22)
- Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. (1996) (22)
- Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7) (2012) (21)
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (20)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
- Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study (2007) (20)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
- whole-exome sequencing identifies (2016) (19)
- Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. (2015) (19)
- Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function (2014) (19)
- Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma (2018) (19)
- Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
- O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab (2020) (18)
- Immunosensitization with a Bcl-2 small molecule inhibitor (2009) (18)
- IL-32γ potentiates tumor immunity in melanoma (2020) (18)
- Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure (2015) (18)
- Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. (2007) (18)
- Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. (2009) (18)
- Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. (2015) (18)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
- Endocrinopathies with use of cancer immunotherapies (2018) (17)
- T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human a Fetoprotein (2001) (17)
- Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. (2004) (17)
- PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. (2010) (17)
- Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B (2020) (17)
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). (2016) (16)
- A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. (2015) (16)
- SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma. (2016) (16)
- Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort (2016) (16)
- Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping. (2017) (16)
- BRAF-targeted therapy and immune responses to melanoma (2013) (16)
- 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma (2015) (16)
- Meeting report from the 2011 international melanoma congress, Tampa, Florida (2012) (16)
- Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. (2013) (16)
- Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006 (2017) (16)
- Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab (2013) (16)
- Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma. (2006) (15)
- SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma. (2015) (15)
- How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. (2021) (15)
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma (2022) (15)
- Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC) (2014) (15)
- Phase II trial of an all‐oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer (1995) (15)
- CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. (2012) (15)
- Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene–modified dendritic cell vaccines (2002) (15)
- 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma (2020) (15)
- Potentiating adoptive cell therapy using synthetic IL-9 receptors (2022) (14)
- Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma. (2020) (14)
- Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7) (2014) (14)
- Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma. (2006) (14)
- Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. (2006) (14)
- A phase 1‐2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma (2010) (14)
- T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. (2014) (14)
- Vincristine (NSC 67574) in non-small cell bronchogenic carcinoma. Results of a phase II clinical study. (1978) (14)
- Impact of MET expression on outcome in BRAFV600E/K advanced melanoma (2013) (14)
- Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E (2017) (14)
- results from a randomised, double-blind, phase 3 trial (2016) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206 (2007) (13)
- At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer (2021) (13)
- PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody (2013) (13)
- Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival. (2006) (13)
- Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. (2007) (13)
- Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
- Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022). (2016) (13)
- First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. (2017) (13)
- Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. (2010) (13)
- Melanoma dedifferentiation induced by IFN- γ epigenetic remodeling in response to anti–PD-1 therapy (2021) (13)
- M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. (1996) (13)
- Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma. (2021) (12)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
- Phase II study of volociximab (M200), an {alpha}5{beta}1 anti-integrin antibody in metastatic melanoma (2006) (12)
- A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication (2018) (12)
- Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone (2016) (12)
- Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
- 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study (2015) (11)
- Therapeutic cancer vaccines. (2007) (11)
- Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis (2019) (11)
- 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma (2020) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44 (2020) (11)
- Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study. (2016) (11)
- Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. (2015) (11)
- Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. (2015) (11)
- Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study (2021) (11)
- CRAF R391W is a melanoma driver oncogene (2016) (11)
- Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types (2021) (10)
- Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma (2016) (10)
- Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. (2021) (10)
- Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (2018) (10)
- Title Combination therapy with vemurafenib ( PLX 4032 / RG 7204 ) and metformin in melanoma cell lines with distinct driver mutations (2011) (10)
- The shifting patterns of metastatic melanoma. (2000) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- HMGB1 Mediates Endogenous TLR2 Activation And Brain Tumor Regression. (2008) (10)
- NK and CD 4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain 1 (2006) (10)
- Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study (2019) (10)
- Comparative Study of Sequential Combinations of Paclitaxel and Methotrexate on a Human Bladder Cancer Cell Line (2000) (10)
- KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. (2017) (10)
- PET imaging of the immune system: immune monitoring at the whole body level. (2010) (10)
- Autoantibody Landscape in Patients with Advanced Prostate Cancer (2020) (9)
- Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
- Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies (2017) (9)
- Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19. (2021) (9)
- Cancer therapy: Tumours switch to resist (2012) (9)
- Impact of COVID-19 Pandemic on Cancer Research (2020) (9)
- Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
- Abstract CT034: Phase I study of WNT974 + spartalizumab in patients (pts) with advanced solid tumors (2020) (9)
- Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). (2014) (9)
- Clinical trials with tumor antigen genetically modified dendritic cells. (2005) (9)
- Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
- Combination Therapies Building on the Efficacy of CTLA4 and BRAF Inhibitors for Metastatic Melanoma. (2012) (8)
- The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. (2020) (8)
- Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy. (2021) (8)
- Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival (2014) (8)
- Broad antitumor protection by dendritic cells administered to CD8α knock out mice (2006) (8)
- Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006 (2021) (8)
- Single cell analytic tools for drug discovery and development (2016) (8)
- Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma. (2016) (8)
- Reply to K.S. Wilson et al. (2013) (8)
- Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain. (1995) (8)
- Interleukin 32 expression in human melanoma (2019) (8)
- Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors. (2013) (8)
- Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients. (2017) (8)
- Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma (2014) (8)
- Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). (2015) (8)
- Kinetic Inference Resolves Epigenetic Mechanism of Drug Resistance in Melanoma (2019) (8)
- Antigen Presentation Keeps Trending in Immunotherapy Resistance (2018) (7)
- Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response (2020) (7)
- SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. (2012) (7)
- Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma. (2021) (7)
- Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716). (2018) (7)
- Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma (2015) (7)
- A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265). (2016) (7)
- Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study. (2015) (7)
- Anti-PD-1 antibody treatment for melanoma. (2018) (7)
- Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses (2022) (7)
- Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib (2018) (7)
- SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173). (2017) (7)
- BRAF +/- MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006 (2018) (7)
- Excluding T Cells: Is β-Catenin the Full Story? (2015) (7)
- Clearance of monoclonal antibody (mAb) CP-675,206 by therapeutic plasma exchange (TPE) or plasmapheresis (2007) (6)
- Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-Dioxygenase (IDO) Expression With the CTLA4 Blocking MAB CP-675,206 (2006) (6)
- Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors (2017) (6)
- Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002. (2015) (6)
- IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System (2018) (6)
- A late complication of tracheostomy. (1977) (6)
- Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy. (2020) (6)
- Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab. (2006) (6)
- Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy (2021) (6)
- Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis (1997) (6)
- ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors (2015) (6)
- Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma. (2015) (6)
- Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. (2016) (6)
- IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy (2021) (6)
- Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (6)
- Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? (2009) (6)
- Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. (2019) (6)
- Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- How Did We Get a COVID-19 Vaccine in Less Than 1 Year? (2021) (6)
- Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC). (2016) (6)
- Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma (2019) (6)
- Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. (2004) (6)
- Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
- 1 PD-1 blockade expands intratumoral T memory cells (2016) (6)
- Priority Report Combinatorial Treatments That Overcome PDGFR b-Driven Resistance of Melanoma Cells to V 600 EB-RAF Inhibition (2011) (6)
- Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting (2013) (6)
- Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma. (2014) (6)
- Gene editing: Towards the third generation of adoptive T-cell transfer therapies (2019) (5)
- Overcoming tumor resistance to immunotherapy (2006) (5)
- Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study. (2017) (5)
- Iron toxicity studies of quelamycin. (1979) (5)
- Immune rejection in a humanized model of murine prostate cancer. (2010) (5)
- Meeting Report from the Third Global Workshop on Melanoma (2010) (5)
- Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis (2021) (5)
- Immunoediting the cancer genome – a new approach for personalized cancer therapy? (2012) (5)
- Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM). (2017) (5)
- Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038 (2017) (5)
- Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma (2020) (5)
- Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma (2016) (5)
- Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report. (2021) (5)
- STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. (2022) (5)
- Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM). (2016) (5)
- First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. (2011) (5)
- SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma. (2015) (5)
- Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. (2017) (5)
- 140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) (2014) (5)
- Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study. (2016) (5)
- Phase II trial of ABI-007 (Abraxane) in previously treated and chemotherapy na??ve patients with metastatic melanoma (2006) (4)
- Abstract CT139: Durability of responses to the combination of SD-101 and pembrolizumab in advanced metastatic melanoma: Results of a phase Ib, multicenter study (2018) (4)
- Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials (2020) (4)
- Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. (2016) (4)
- Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib (2021) (4)
- 1093PDVEMURAFENIB AND COBIMETINIB POTENTLY INHIBIT PS6 SIGNALING IN BRAFV600 MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC MELANOMA FROM BRIM7 STUDY. (2014) (4)
- Long term Survival with CTLA-4 blockade Using Tremelimumab (2016) (4)
- Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling. (2010) (4)
- Immunotherapy of hepatocellular carcinoma (2002) (4)
- Results of two sequential chemotherapy studies in WHO Types I, III and IV lung cancer: cyclophosphamide-5-fluorouracil (CF) and cyclophosphamide-5-fluorouracil-adriamycin (CAF). (1979) (4)
- Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). (2012) (4)
- Collaborative Care in Melanoma: The Essential Role of the Nurse . (2017) (4)
- Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206). (2006) (4)
- Genomic biomarkers in relation to PD-1 checkpoint blockade response. (2018) (4)
- Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California (2013) (4)
- Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616). (2018) (4)
- Combinatorial effect of dabrafenib, trametinib, and adoptive cell transfer (ACT) in an immune-competent murine model of BRAFV600E mutant melanoma. (2014) (4)
- Germ-line biomarkers disrupting microRNA regulatory pathways to predict toxicity and response to anti-PD-1 and anti-PD-L1 therapies. (2017) (4)
- Selective and Nonselective Replication of an E 1 B-deleted Adenovirus in Hepatocellular Carcinoma 1 (1999) (4)
- Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis (2016) (4)
- Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. (2021) (4)
- Triple therapy for BRAF V600-mutated melanoma (2020) (4)
- Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma (2008) (4)
- coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2014) (4)
- Erratum: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors (American Society for Clinical Investigation (2013) 123:3 (1371-1381) DOI 10.1172/JCI66236) (2013) (4)
- Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma. (2014) (3)
- Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10 (2021) (3)
- Inside Back Cover: Polymer Nanofiber‐Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells (Angew. Chem. Int. Ed. 12/2013) (2013) (3)
- Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade. (2020) (3)
- Title Effect of dabrafenib on melanoma cell lines harbouring the BRAF V 600 D / R mutations Permalink (2013) (3)
- Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. (2022) (3)
- 950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma (2021) (3)
- Exosomes as a predictor tool of acquired resistance to melanoma treatment (2014) (3)
- 18TiPPhase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors (2015) (3)
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation (2021) (3)
- Acquired resistance to T cell adoptive transfer by inflammation-induced melanoma dedifferentiation. (2018) (3)
- Function in a Human Melanoma Model MHC Class I-Restricted Cytolytic Effector TCR Synthesize Th 1 Cytokines and Exhibit MHC Class I-Restricted Epitope-Specific T Cells Transduced to Express − CD 25 + CD 4 Baltimore and Bijay Mukherji (2008) (3)
- Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy (2022) (3)
- Reprogramming human T cell function and specificity with non-viral genome targeting (2018) (3)
- Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL). (2015) (3)
- Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma (2015) (3)
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. (2019) (3)
- IRIS: Big data-informed discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing (2019) (3)
- Abstract CT008: A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab in patients with sarcoma and melanoma (2018) (3)
- Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy (2022) (3)
- T Cell Immunotherapy: Optimizing Trial Design (2014) (3)
- Ionizing radiation affects tumor antigen presentation by dendritic cells (2003) (3)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
- Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. (2016) (3)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
- Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma (2010) (3)
- Abstract NG04: Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations (2017) (3)
- A Pooled analysis of 655 patients with advanced melanoma enrolled in keynote-001 : long-term efficacy of pembrolizumab (mk-3475) (2015) (3)
- T Cells as the Future of Cancer Therapy. (2021) (3)
- Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
- Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products (2018) (3)
- ClassifyingCancersBasedonT-cell In fi ltrationand PD-L 1 (2015) (3)
- Abstract NG11: Landscape analysis of neoepitope-specific T-cell responses to immunotherapy (2020) (3)
- Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma. (2016) (3)
- A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma. (2012) (3)
- PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. (2017) (2)
- Adhering to the guidelines: rates of BRCA mutation using NCCN genetic testing criteria (2017) (2)
- Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/Rmutations (2013) (2)
- Defective Nucleotide Catabolism Defines a Subset of Cancers Sensitive to Purine Nucleoside Phosphorylase Inhibition (2019) (2)
- Abstract S03-01: Pan-HLA prediction of SARS-CoV-2 epitopes (2020) (2)
- P2.09-05 Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001 (2018) (2)
- Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. (2022) (2)
- Trying for a BRAF Slam Dunk. (2020) (2)
- 3340 Treatment beyond progression in advanced BRAF-mutated melanoma with vemurafenib and cobimetinib: Results from the BRIM7 trial (2015) (2)
- Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations (2015) (2)
- Current Deve lopments in Cancer Vacc ines and Cel lu lar Immunotherapy (2003) (2)
- Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. (2018) (2)
- Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results (2012) (2)
- Clinical and Immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi-institutional phase II clinical trial (2007) (2)
- Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens (2023) (2)
- Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer (2022) (2)
- Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. (2020) (2)
- Abstract CT125: A phase III randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404 (2016) (2)
- Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
- When Cancer Cells Become the Enablers of an Antitumor Immune Response. (2022) (2)
- Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors (2016) (2)
- Heterogeneous immunological recovery trajectories revealed in post-acute COVID-19 (2021) (2)
- Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) (2022) (2)
- Cancer Therapy : Clinical CTLA 4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (2014) (2)
- Association of maintenance of pre-existing memory T-cell responses following anti-CTLA-4 antibody treatment with improved overall survival. (2014) (2)
- 1224PDAnalysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002 (2017) (2)
- Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. (1997) (2)
- AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma. (2022) (2)
- Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008 (2009) (2)
- Effect of anti-CTLA-4 antibody treatment on T-cell repertoire evolution in treated cancer patients. (2013) (2)
- [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]. (1996) (2)
- CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma. (2012) (2)
- Novel insights/translational implication from the emerging biology of melanoma. (2014) (2)
- CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (2022) (2)
- Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. (2018) (2)
- Multi-modal single-cell and whole-genome sequencing of minute, frozen specimens to propel clinical applications (2022) (2)
- Presentation by Dendritic Cells Melanoma Antigen Processing and Ionizing Radiation Affects Human MART-1 (2013) (2)
- 1131TiPPHASE 1 STUDY EVALUATING SAFETY AND TOLERABILITY OF MEDI4736, AN ANTI-PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) ANTIBODY, IN COMBINATION WITH DABRAFENIB AND TRAMETINIB OR TRAMETINIB ALONE IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (2014) (2)
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects (2021) (2)
- A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy. (2004) (1)
- AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
- Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
- Phase I/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma (2008) (1)
- S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma. (2020) (1)
- Accurate neoantigen prediction depends on mutation position relative to patient allele-specific MHC anchor location (2020) (1)
- Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors (2022) (1)
- Abstract 915: Melanomas with rare BRAF mutations and their responses to MAPK pathway blocking drugs. (2013) (1)
- Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006 (2018) (1)
- Sensitive, Non‐Destructive Detection and Analysis of Neoantigen‐Specific T Cell Populations from Tumors and Blood (2018) (1)
- Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). (2019) (1)
- A Histone Deacetylase Inhibitor (HDACI) Sensitizes B16 Melanoma to Adoptive Transfer (AT) Immunotherapy (2006) (1)
- Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma (Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA.) (2019) (1)
- Reply to Perris, Borghese, and Magro (2011) (1)
- TCR use and cytokine response in PD-1 blockade. (2015) (1)
- Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. (2022) (1)
- ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors (2015) (1)
- 1075TiPKEYNOTE-029: PHASE 1/2 STUDY OF MK-3475 IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2B (PEG-IFN) OR IPILIMUMAB (IPI) IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) OR RENAL CELL CARCINOMA (RCC). (2014) (1)
- Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet (2015) (1)
- Abstract 2682: Melanoma phenotype switching to adapt to BRAF inhibition (2015) (1)
- Evaluation of pre-analytical factors affecting plasma DNA analysis (2018) (1)
- Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity (2022) (1)
- Abstract 5015: TCR usage analysis in blood reveals different mechanisms of action of CTLA-4 and PD-1 blockade in patients (2014) (1)
- Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM) (2019) (1)
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma (2014) (1)
- Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy (2023) (1)
- Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy (2022) (1)
- Cancer Immunotherapy & Immuno-monitoring: Mechanism, Treatment, Diagnosis, and Emerging Tools (2014) (1)
- BRAF and MEK Inhibitors (2013) (1)
- Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies (2019) (1)
- Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade (2022) (1)
- Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma (2016) (1)
- S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma. (2021) (1)
- Innenrücktitelbild: Polymer Nanofiber‐Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells (Angew. Chem. 12/2013) (2013) (1)
- Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006 (2017) (1)
- KIR Genetics Modifies Susceptibility to Inflammatory Disorder by Reprogramming Human Natural Killer Cell Function (2012) (1)
- Abstract 4755: Role of PAK4 in cancer immune cell exclusion (2018) (1)
- Human glioma cell models resistant to alloreactive cytotoxic T lymphocytes (2004) (1)
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (1)
- Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma (2014) (1)
- Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study (2017) (1)
- Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). (2019) (1)
- A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (1)
- Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy (2021) (1)
- Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer (2009) (1)
- Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations (2016) (0)
- Abstract PR09: Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies (2018) (0)
- Abstract 656: Antitumor activity of combined therapy with the class I BRAF inhibitor PLX4032 and immunotherapy (2011) (0)
- Abstract 1925: MHC class I-restricted MART-127-35 specific TCR engineered human CD4+ and CD8+ T cells exhibit polyfunctional properties (2010) (0)
- Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy (2018) (0)
- Abstract B023: Antibody blockade of Semaphorin 4D enhances infiltration of APC and CD8 T cells and reduces immune suppression to facilitate immune-mediated tumor rejection (2016) (0)
- Abstract 1697: Signaling pathways involved in melanoma cell functions and dedifferentiation induced by inflammatory cytokines (2020) (0)
- Abstract 5013: Toward better selection of PD-1 blockade responders through direct markers of adaptive immune resistance (2015) (0)
- 162 Resistance to RAF Inhibitors Due to RAS-independent Dimerization of BRAF(V600E) Splicing Variants (2012) (0)
- Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320. (2020) (0)
- PLENARY SESSION 8: NEW FRONTIERS IN IMMUNOTHERAPY (2): NEW TARGETS AND AGENTS BEYOND CHECKPOINT INHIBITION (2015) (0)
- Abstract 3006: Melanoma cell lines derived from patient derived xenografts (PDX) can contain murine chromosomes resultant from cell fusions (2021) (0)
- Abstract B011: Immunoediting in untreated mismatch repair deficient colorectal cancer (2018) (0)
- Abstract 879: Single cell analysis resolves combinatory targeted therapy for arresting the BRAFi-induced cellular dedifferentiation of metastatic melanomas (2016) (0)
- Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7) (2014) (0)
- [Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases]. (1994) (0)
- Abstract 5017: T-cell repertoire turnover induced by anti-CTLA-4 antibody treatment in cancer patients (2014) (0)
- Abstract 5639: Computational prediction of MHC anchor locations guide neoantigen prediction and prioritization (2022) (0)
- A Pre-Clinical Model Of Hematopoietic Stem Cell Based Immunotherapy For Cancer Utilizing The NY-ESO-1 T-Cell Receptor and sr39TK PET Reporter / Suicide Gene (2013) (0)
- Abstract CT023: Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma (2023) (0)
- OR.96. MHC Class I-Restricted Human Melanoma Epitope Specific TCR Engineered Human CD4 T Cells Exhibit Anti-Tumor Effector Function, Proliferate upon Cognate Stimulation, Amplify CD8+CTL Generation, and Mitigate Inducible T Regulatory Cell (iTreg) Activities in Human Melanoma, in vitro (2009) (0)
- MP35-06 EFFECTS OF DENDRITIC CELL-BASED AD-GM∙CAIX VACCINE AS MONOTHERAPY OR IN COMBINATION WITH SUNITINIB IN AN IMMUNOCOMPETENT MOUSE MODEL OF METASTATIC RENAL CELL CARCINOMA (2014) (0)
- Abstract 553: Melanoma subtypes that emerge during adaptive resistance to therapy are targets for bispecific T cell engager (BiTE®) antibody constructs directed to CDH19 and DLL3 (2019) (0)
- Abstract CT065: KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma (2017) (0)
- Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. (2009) (0)
- Abstract 6590: Epigenetic suppression of transgenic T-cell receptor (TCR) expression in adoptive cell transfer (ACT) therapy (2020) (0)
- Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy (2019) (0)
- Histone deacetylase inhibitor, LBH589, synergizes with an immunotherapy treatment in an in vivo murine brain tumor model (2009) (0)
- Abstract 6585: Systems biology for investigating drug resistance mechanism of melanoma (2020) (0)
- 1257TiPKEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma (2017) (0)
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
- Peptides with antimicrobial action. (2000) (0)
- 1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial (2021) (0)
- Abstract 3584: Effects of the investigational selective MEK inhibitor TAK-733 against cutaneous and uveal melanoma cell lines (2011) (0)
- Safety and tolerability of 1-hour intravenous infusion of tremelimumab (CP-675,206) in patients with surgically incurable stage III or IV melanoma. (2009) (0)
- Abstract 765: Hybridized-capture sequencing methods bias analysis of antigen presentation genes (2022) (0)
- Abstract A05: Pharmacodynamics of immune checkpoint blockade therapy indicate drivers of response (2020) (0)
- Abstract IA17: Technologies for personalizing cancer immunotherapies (2017) (0)
- Generation of Dendritic Cells after One-Hit Lentiviral Transduction of Hematopoietic Precursor Cells: Proof of Concept for the Human and Mouse Systems. (2004) (0)
- 424. Myd88/TLR Signaling Is Required for Immunotherapy-Mediated Glioblastoma Regression (2006) (0)
- Abstract 928: Preventing melanoma from healing itself after therapy-induced immune attack through IPRES blockade (2019) (0)
- Abstract PR03: CD8+ T-cell distribution and immunomodulator expression in BRAF-mutant melanoma affect the response to BRAF inhibitor and chemotherapy (2015) (0)
- 129 INVITED Combining TKI's in Melanoma: Which Rationale, How and When (2011) (0)
- Melanoma Bridge 2013: Poster and Oral (2014) (0)
- Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials (2016) (0)
- Association of loss of adaptive PD-L1 expression with upregulation of PBRM1 chromatin regulator in melanoma. (2018) (0)
- Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line (2020) (0)
- Acid Assembled p / MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells (2009) (0)
- Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2021) (0)
- T cell antigen discovery via signaling and antigen-presenting bifunctional receptors (2019) (0)
- Abstract NG11: Orthogonal IL-9 receptor signaling reprograms T cells to obviate conditioning chemotherapy before adoptive cell therapy (2021) (0)
- Histone deacetylase inhibitor, LBH589, synergizes with an immunotherapy treatment in an in vivo murine brain tumor model (41.35) (2009) (0)
- Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (0)
- Phase I/II trial of Amplimexon (imexon, inj.) plus dacarbazine in patients with stage III or IV malignant melanoma (2006) (0)
- 932 High dose continuous infusion (CI) ifosfamide without hematopoietic support in heavily pretreated breast cancer (BC) and sarcoma (S) patients (1995) (0)
- T cell antigen discovery via trogocytosis (2019) (0)
- A Promising Era in Melanoma Treatment: Role of Combination Therapies (2015) (0)
- Abstract 3661: Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies (2017) (0)
- Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials (2016) (0)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
- Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors (2012) (0)
- Optimizing nucleic acid extraction and transcriptome evaluation from low-input, fixed clinical samples (2020) (0)
- Abstract LB-428: RAS-independent dimerization of BRAF(V600E) splicing variants promotes resistance to RAF inhibitors (2012) (0)
- Current D evelopments i n C ancer V accines a nd Cellular I mmunotherapy (2003) (0)
- Introduction: Cancer vaccines—mechanisms and a clinical overview (2011) (0)
- Clonally-Expanded, Thyrotoxic Autoimmune Mediator CD8+ T cells Driven by IL21 Contribute to Checkpoint Inhibitor Thyroiditis (2022) (0)
- [Corticoid treatment in Castleman's disease]. (1995) (0)
- HMGB1 Is Released into the Supernatant of GL26, LLc1, GL261, and B16-F10 Tumor Cell Lines in Response to Treatment with Ad-TK (+GCV), Irradiation, or Temozolomide (2009) (0)
- Q&A: Antoni Ribas on immunotherapy progress. (2012) (0)
- 123 Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy (2022) (0)
- Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma (2023) (0)
- Abstract 2819: Efficacy and safety of the Ad-GM·CAIX dendritic cell-based vaccine in treatingin vivometastatic renal cell carcinoma compared to sunitinib monotherapy and simultaneous vaccine-sunitinib combination therapy (2014) (0)
- Safety and efficacy of dendritic cell immunotherapy with ad-GMCAIX in an immunocompetent preclinical tumor model of renal cell carcinoma. (2012) (0)
- Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i (2020) (0)
- Abstract 1563:In vivosafety and efficacy of a novel dendritic cell based Ad-GMCAIX vaccine with activity against renal cell carcinoma (2012) (0)
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion (2012) (0)
- 1241PImpact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis (2017) (0)
- Abstract 3210: Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA) (2020) (0)
- Abstract 2325: IRF1 displays opposing tumor cell-intrinsic and -extrinsic roles in anti-tumor immunity (2023) (0)
- Abstract 3605: Human chimeric orthogonal IL9 receptor signaling promotes stemness and polyfunctionality for adoptive T cell therapy of cancer (2022) (0)
- CTLA-4 Blocking Monoclonal Antibodies in the Treatment of Metastatic Melanoma (2006) (0)
- Computational prediction of MHC anchor locations guide neoantigen identification and prioritization (2022) (0)
- 1478 A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells (2022) (0)
- Cyclic cell state transition is associated with the adaptive resistance to BRAF inhibition in melanomas (2018) (0)
- Abstract 2671: Antitumor activity of NKTR-214 in combination with pmel-1 ACT in an aggressive murine melanoma model (2017) (0)
- Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma (2015) (0)
- 61. Higher In Vivo Maintenance, Biodistribution and Immunopotency of Dendritic Cell Vaccines Self-Differentiated through Lentiviral Vector Programming (2005) (0)
- Potentiating adoptive cell therapy using synthetic IL-9 receptors (2022) (0)
- Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma (2023) (0)
- 73INCOMBINING IMMUNOTHERAPIES. (2014) (0)
- [Clinical development of antitumoral vaccines]. (2002) (0)
- 621. Immunological Memory in a Syngeneic Model of Recurrent and Multifocal Glioblastoma (2006) (0)
- Autoantibody landscape of advanced prostate cancer (2020) (0)
- [Antitumor immunology in the year 2000 and the new immunosuppressive therapy]. (2000) (0)
- Abstract 2069: Overcoming drug resistance by targeting melanoma dedifferentiation through information-theoretic analysis and single cell proteomics (2017) (0)
- Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines (2012) (0)
- Abstract LB208: Obesity is associated with lower tumor oxidative phosphorylation (OXPhos) in metastatic melanoma (MM) (2021) (0)
- T Cell Responses to Alpha Fetoprotein-Derived Immunodominant Peptide-Pulsed Dendritic Cells in Patients with Hepatocellular Cancer (2004) (0)
- Combination Therapy for Metastatic Melanoma (2016) (0)
- Interleukin 32 expression in human melanoma (2019) (0)
- Abstract A65: Improved immunological responses against melanoma in vivo with T lymphocyte adoptive cell therapy coupled with targeted inhibition of mutated and activated BRAF (2011) (0)
- Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma (2020) (0)
- 1277 Transduction and selection of murine tumor cells engineered to express the interleukin 2 (IL-2) and herpes simplex virus thymidine kinase (HSVTK) genes (1995) (0)
- Abstract 3818: Infrequent chromosomal loss and recurrent gains lead to imbalanced expression of HLA genes in melanoma (2022) (0)
- Cells in the Absence of CD8-Positive Cells Enhanced Tumor Responses to Dendritic (2013) (0)
- DENDRITIC CELLS AND VACCINES Treatment ofMetastatic Colorectal Cancer Patients with a Tumor Lysate Pulsed Dendritic Cell Vaccine: A Randomized Evaluation of Ex Vivo CD40L Activation (2004) (0)
- Abstract 5965: B2M loss of heterozygosity in melanoma is associated with increased numbers of activated NK cells and higher expression of the NK cell inhibitory ligand, HLA-G (2023) (0)
- 1292 A reproducible pipeline for analysis of multiplex imaging (MIBI) data with application to uncovering novel features of the tumor-immune microenvironment (2022) (0)
- Standardization of MHC Tetramer and ELISPOT Assays To Quantitate Antigen-Specific T Cell Expansion after CTLA4 Blockade (2004) (0)
- Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib (2021) (0)
- ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways (2017) (0)
- Abstract LB251: Blocking genomic instability delays acquired resistance to MAPK inhibitor therapy in melanoma (2023) (0)
- Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01) (2017) (0)
- [Gene therapy: new prospects in the treatment of cancer]. (1994) (0)
- Identification of RORg+T Cells as Key Players in Thyroid Autoimmunity From Checkpoint Immunotherapy (2021) (0)
- Abstract 634: Combinatorial targeting in melanoma cell lines with defined and distinct mechanisms of acquired resistance toV600EB-RAF inhibition (2011) (0)
- Abstract 1762: Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy (2018) (0)
- A phase I trial of intra-lymph-node administration of a novel immunotherapeutic regimen (MKC1106-MT) in patients with advanced melanoma. (2010) (0)
- ClassifyingCancersBasedonT-cell Infiltrationand PD-L1 (2015) (0)
- Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma (2016) (0)
- 426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma (2020) (0)
- Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006 (2016) (0)
- Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib. (2020) (0)
- Abstract 914: Preinfusion polyfunctional profiles and cytokine secretion activity of transgenic TCR-T cells, and serum cytokine profiles, are associated with clinical outcomes in sarcoma and melanoma (2023) (0)
- Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response. (2017) (0)
- Abstract 917: High antitumor activity of the ERK inhibitor SCH722984 against BRAF-mutant, NRAS-mutant and wild-type melanoma cell lines. (2013) (0)
- Abstract 147: Improving antitumor effects of a BRAF inhibitor with a colony stimulating factor 1 receptor (CSF-1R) inhibitor, PLX3397 (2014) (0)
- 1069P Granulomatous and sarcoid-like immune adverse events following CTLA4 and PD1 blockade adjuvant therapy of high-risk melanoma: A combined analysis of ECOG-ACRIN E1609 and SWOG S1404 phase III trials (2021) (0)
- 3 in a Murine Melanoma Syngeneic Model Requires 4 Costimulation, CD4, and CD8 T Cells (2016) (0)
- Technologies for personalizing cancer immunotherapies (2017) (0)
- 30. Semi-automated approaches for digital pathology analyses standardize pathologic assessment of clinical melanoma biopsies (2022) (0)
- Cancer Therapy: Clinical Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (0)
- Abstract 4527: CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616 (2023) (0)
- 1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma (2020) (0)
- Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
- Abstract C138: Loss of NF1 in melanoma cell lines is associated with active Ras and dependence on MEK even in the absence of BRAF or NRAS mutation. (2013) (0)
- Modeling Mitogen-activated Protein Kinase Pathway Activity In Novel Uveal Melanoma Cell Lines (2011) (0)
- Abstract 3275: Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (2023) (0)
- A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy. (2019) (0)
- Abstract 3566: Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214 (2018) (0)
- Abstract NG04: Immune evasion mechanisms in melanoma resistant to targeted- and/or immunotherapy (2018) (0)
- Which therapy for which patient (2012) (0)
- Role of CD4 cells in the complete anti-tumor response to PD1 blockade in a syngeneic murine melanoma model with activated WNT signaling. (2018) (0)
- Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis (2019) (0)
- Malignant lymphoproliferative diseases (MLD) in patients seropositive for the HIV (1993) (0)
- Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. (2018) (0)
- Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma (2023) (0)
- Abstract 361: PET imaging of antitumor responses with anti-4-1BB (anti-CD137) (2012) (0)
- Interrogating resistance mechanisms to PD-1 blockade therapy with CRISPR. (2017) (0)
- Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). (2022) (0)
- Invariant HLA-E T Cells, a Prevalent Human T Cell Population Endogenously Programmed for Cytolysis, IL-22 Production, and Immune Regulation (2010) (0)
- Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire (2015) (0)
- Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: An analysis of 1670 high-risk patients. (2021) (0)
- Adenovirus Lymphocytes by Dendritic Cells Transduced Generation of Melanoma-Specific Cytotoxic T (1998) (0)
- 1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
- Abstract 4407: Leveraging spatial profiling combined with bulk RNA sequencing to study patient-specific immunotherapeutic mechanisms (2020) (0)
- ASCO: Impact of 2 New Drugs for the Treatment of Metastatic Melanoma (2011) (0)
- Melanoma Bridge 2013: Poster and Oral Presentations (2014) (0)
- Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy (2020) (0)
- Abstract 4413: Accurate neoantigen prediction depends on mutation position relative to patient-specific MHC anchor location (2020) (0)
- Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and A Literature Review (2023) (0)
- Abstract 3155: Interferon-gamma-induced melanoma plasticity and response to PD-1 blockade therapy (2020) (0)
- Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF (2012) (0)
- 1225PDPrognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib (2017) (0)
- Anti-tumor activity and trafficking of self , tumor-specific T cells against tumors located in the brain , a , b (2009) (0)
- Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma (2014) (0)
- Comprehensive, longitudinal T cell functional analyses correlated with clinical outcome of a melanoma immunotherapy trial (53.18) (2012) (0)
- SWOG S1512: A phase II and pilot trial of pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM). (2018) (0)
- Immune-mediated brain tumor regression requires HMGB1 release and subsequent TLR2 activation on tumor infiltrating dendritic cells (2008) (0)
- PD-L1 EXPRESSION AND EFFICACY IN PATIENTS TREATED WITH PEMBROLIZUMAB VS IPILIMUMAB FOR ADVANCED MELANOMA IN KEYNOTE-006 (2016) (0)
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma (2019) (0)
- Abstract SY03-04: Novel imaging approaches for immunotherapy and targeted therapy of melanoma in animal models and humans (2011) (0)
- Abstract 4532: Spatial profiling delineates tumor-T-cell dynamics in anti-PD-1-refractory melanoma treated with ipilimumab or ipilimumab plus nivolumab (2023) (0)
- Engineering antigen-specific T cells for in vivo imaging: A study of the dynamic biological interactions in anti-tumor immunity (2007) (0)
- P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma (2020) (0)
- CD1-restricted Natural Killer T Cells Murine Hepatocellular Carcinoma Model Is Not Dependent on Adenovirus-Interleukin-12-mediated Tumor Regression in a (2013) (0)
- Comparison of a combined MHC tetramer and interferon-γ (IFN-γ) intracellular cytokine staining (ICS) assay with individual MHC-tetramer and IFN-γ ELISPOT assays to monitor cancer immunotherapy (2007) (0)
- cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. (2011) (0)
- Treating Cancer with PD-1 Blockade (2015) (0)
- Associationism for after a crisis (1990) (0)
- Q1 Classifying Cancers Based on T-cell In fi ltration and 3 PD-L1 Q2 (2015) (0)
- Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma (2015) (0)
- Abstract 2144: A novel method for high-throughput discovery of neo-antigens and corresponding T-cell receptors (2017) (0)
- 2 Response to Programmed Q 1 Cell Death-1 Blockade Q 2 3 in a Murine Melanoma Syngeneic Model Requires 4 Costimulation , CD 4 , and CD 8 T Cells 5 (2016) (0)
- Trajectories from Snapshots: Integrated proteomic and metabolic single-cell assays reveal multiple independent adaptive responses to drug tolerance in a BRAF-mutant melanoma cell line (2019) (0)
- 111. pVACsplice: Predicting neoantigens from tumor-specific alternative splicing events derived from regulatory mutations (2022) (0)
- Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. (1997) (0)
- 304 DC-AD-GMCAIX BASED VACCINE THERAPY IS SAFE AND EFFECTIVE IN IMMUNOCOMPETENT MURINE KIDNEY CANCER TUMOR MODELS (2012) (0)
- Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. (2023) (0)
- Erratum: CTLA4 blockade broadens the peripheral T-cell receptor repertoire (Clinical Cancer Research (2014) 20 (2424-2432)) (2015) (0)
- O8.2Putting adoptive T cell therapy on the path to regulatory approval (2015) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition (2015) (0)
- Abstract 3510: Paradoxical MAPK activation and beneficial effects of vemurafenib on T-cell phenotype resulting in improved functionalityin vivo (2012) (0)
- Tumor Antigen-Specific T Cell Responses in Hepatocellular Cancer Patients (2006) (0)
- Abstract 5518: Characterization of invariant natural killer T cells in patients with advanced melanoma treated with CTLA4 blockade and dendritic cell vaccination (2011) (0)
- Abstract IA17: PD-1 blockade therapy for cancer (2015) (0)
- Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma (2017) (0)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (0)
- Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique (2014) (0)
- S1773 Invariant HLA-E T Cells, a Prevalent Human T Cell Population Endogenously Programmed for Cytolysis, IL-22 Production, and Immune Regulation (2010) (0)
- Velcade ) with the Proteasome Inhibitor Bortezomib Dendritic Cell-Activated Immune Responses Immunosensitization of Tumor Cells to (2006) (0)
- Title Combination Treatment for Melanoma Permalink (2014) (0)
- Abstract 1551: Phenotypic characteristics of T cells co-expressing SOX2, OCT3/4, and NANOG (2021) (0)
- Tumour-intrinsic resistance to immune checkpoint blockade (2019) (0)
- Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma (2014) (0)
- Abstract LB152: CAR-T cell therapy for melanoma targeting surface expression of TYRP-1 (2021) (0)
- The essential role of the nurse (2020) (0)
- Abstract 4839: Adoptive cell transfer of transgenic T cells elicited a two-wave antitumor cellular immune response consisted of engineered and endogenous T lymphocytes with different sets of functions (2012) (0)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
- Generation of Lenti-Virus Mediated JNK and Apoptosis Inducing Factor (AIF) Knockout Cell Lines: Involvement of JNK & AIF in FAS and TNF-Alpha Mediated Cell Death Pathways (2006) (0)
- Characterization of Melanoma Antigen-Specific T Cells in a Long Term Survivor with Metastatic Melanoma with a Stable Peripheral Blood Population of Greater Than 5% of MART-1-Specific CD8+ T Cells (2004) (0)
- Genetic Re-programming of Stem Cells to Fight Cancer (2018) (0)
- 65. Accurate neoantigen prediction depends on mutation position relative to patient-specific MHC anchor locations (2020) (0)
- Abstract 1388: Mutations in transcriptional activators of MHC I antigen presentation, NLRC5 and CIITA, are mutually exclusive and have different effects on melanoma gene transcripts (2022) (0)
- Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933. (2012) (0)
- Abstract 3969: Blocking colony stimulating factor 1 receptor (CSF1R) improves anti-tumor effects of adoptive T cell transfer therapy. (2013) (0)
- Abstract SY26-02: Complex immune effects of inhibiting BRAF (2015) (0)
- Abstract 1937: Enhanced tumor control with adoptive transfer of TCR engineered T cells expressing Tcl1 (2010) (0)
- 2 In fi ltration of CD 8 T Cells Q 1 and Expression of 3 PD-1 and PD-L 1 in Synovial Sarcoma Q 2 4 (2017) (0)
- Abstract IA10: The interferon receptor pathway's role in response and resistance to PD-1 blockade (2017) (0)
- Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors. (2017) (0)
- Abstract 674: CRISPR and drug screens identify ERK as the mediator of IFNg-induced melanoma growth inhibition (2023) (0)
- Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist (2020) (0)
- Abstract 1215: pVACsplice: Predicting neoantigens from tumor-specific alternative splicing events derived from cis-acting regulatory mutations using whole exome and RNA sequencing data (2022) (0)
- 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma (2021) (0)
- Abstract 3765: IND-Enabling GLP study to support a clinical trial of dual adoptive cell therapy combining stem cells and T cells engineered with an NY-ESO-1 TCR (2017) (0)
This paper list is powered by the following services:
Other Resources About Antoni Ribas
What Schools Are Affiliated With Antoni Ribas ?
Antoni Ribas is affiliated with the following schools:
